Gastric Cancer

>

Latest News

Findings from the phase 3 CheckMate 649 trial support nivolumab plus chemotherapy as a standard frontline therapy for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Nivolumab/Chemo Yields Meaningful Survival in Advanced Gastric/GEJ Cancer

March 13th 2024

Findings from the phase 3 CheckMate 649 trial support nivolumab plus chemotherapy as a standard frontline therapy for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Data from the phase 3 RATIONALE 305 trial support the biologics license application for tislelizumab plus chemotherapy in advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
FDA Accepts BLA for Tislelizumab/Chemo in Gastric/GEJ Adenocarcinoma

February 27th 2024

Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer

February 18th 2024

Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma

February 7th 2024

Total Gastrectomy Associated with Long-term AEs in CDH1 Variants
Total Gastrectomy Associated with Long-term AEs in CDH1 Variants

January 23rd 2024

More News